Currency In USD
| Previous Close | 221.38 |
| Open | 221.38 |
| Day High | 221.38 |
| Day Low | 221.38 |
| 52-Week High | 221.42 |
| 52-Week Low | 15.22 |
| Volume | 2.69M |
| Average Volume | 1.37M |
| Market Cap | 5.61B |
| PE | -19.77 |
| EPS | -11.2 |
| Moving Average 50 Days | 187.66 |
| Moving Average 200 Days | 84.67 |
| Change | 0 |
Data not available
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
GlobeNewswire Inc.
Nov 24, 2025 1:00 PM GMT
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 06, 2025 9:07 PM GMT
Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2
Cidara Therapeutics to Participate in November Investor Conferences
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will